BioAtla Inc.’s Initial Public Offering of Common Stock
January 04, 2021
Cravath represented the underwriters, J.P. Morgan Securities, Jefferies, Credit Suisse and BTIG, in connection with the $217 million initial public offering of common stock of BioAtla, Inc., a biopharmaceutical company that develops highly specific and selective antibody‑based therapeutics for the treatment of solid tumor cancer. The transaction closed on December 18, 2020.
The Cravath team included partners William V. Fogg and Michael E. Mariani and associates Sarah K. Johnson and Kevin L. Cheng on capital markets matters, and associate Carlos Nicholas Obando on tax matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1991, Columbia Law SchoolHarlan Fiske Stone Scholar
-
A.B., 1988, Brown Universitymagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2009, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.B.A., 2009, Columbia University
-
B.A., 2004, Tufts UniversityPhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
January 04, 2021
New Fortress Energy Inc.’s Registered Primary Common Stock Offering and Concurrent High‑Yield Senior Secured Notes Offering
Cravath represented New Fortress Energy Inc. in connection with its $300 million registered primary common stock offering. Cravath also represented New Fortress Energy, Inc. in connection with its concurrent $250 million 144A/Reg. S high‑yield senior secured notes offering. New Fortress Energy Inc. is a global integrated gas‑to‑power infrastructure company. The transactions closed on December 18, 2020 and December 17, 2020, respectively.
Deals & Cases
December 31, 2020
TG Therapeutics, Inc.’s Registered Primary Common Stock Offering
Cravath represented the underwriters, led by J.P. Morgan Securities, Goldman Sachs & Co. LLC, Evercore ISI and Cantor, in connection with the $316 million registered primary common stock offering of TG Therapeutics, Inc., a biopharmaceutical company dedicated to developing and delivering medicines for patients with B‑cell mediated diseases. The transaction closed on December 17, 2020.
Deals & Cases
December 11, 2020
The Chemours Company’s High-Yield Senior Notes Offering
Cravath represented the initial purchasers, led by J.P. Morgan Securities, Citigroup, Credit Suisse, RBC Capital Markets, Barclays, HSBC, Deutsche Bank Securities, TD Securities and BofA Securities, in connection with the $800 million 144A/Reg. S high-yield senior notes offering of The Chemours Company, a leading global provider of performance chemicals. Cravath also represented the dealer manager in connection with The Chemours Company's concurrent $907 million cash tender offer and solicitation of consents. The tender offer expired on November 25, 2020 and the senior notes offering closed on November 27, 2020.
Deals & Cases
December 09, 2020
L3Harris Technologies, Inc.’s Registered Notes Offering
Cravath represented the underwriters, led by Barclays, HSBC, J.P. Morgan Securities and Morgan Stanley, in connection with the $650 million registered notes offering of L3Harris Technologies, Inc., a global aerospace and defense technology innovator. The transaction closed on November 25, 2020.
